OOIR: Observatory of International Research

Papers

(The TQCC of Molecular Neurodegeneration is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	332
Regulation of the hippocampal translatome by Apoer2-ICD release	205
Tau interactome and RNA binding proteins in neurodegenerative diseases	202
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	182
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	182
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	180
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	180
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	166
Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases	157
Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model	154
Neuroprotection by WldS depends on retinal ganglion cell type and age in glaucoma	151
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	147
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration	139
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	137
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	136
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	133
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	121
Multi-region brain transcriptomic analysis of amyotrophic lateral sclerosis reveals widespread RNA alterations and substantial cerebellum involvement	116
Sex dependent glial-specific changes in the chromatin accessibility landscape in late-onset Alzheimer’s disease brains	114
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	113
Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	108
Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	108
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	106
The role of NURR1 in metabolic abnormalities of Parkinson’s disease	94
Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition	90

Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	88
Correction: Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	87
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	85
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease	84
BAX activation in mouse retinal ganglion cells occurs in two temporally and mechanistically distinct steps	81
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	80
Combination therapy using GDNF and cell transplant in Parkinson’s disease	79
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	68
Repetitive transcranial magnetic stimulation alleviates motor impairment in Parkinson’s disease: association with peripheral inflammatory regulatory T-cells and SYT6	68
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	66
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function	63
Correction: The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	63
Deficits in mitochondrial TCA cycle and OXPHOS precede rod photoreceptor degeneration during chronic HIF activation	63
ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses	63
A perspective on Alzheimer’s disease: exploring the potential of terminal/paradoxical lucidity and psychedelics	63
Correction: HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	62
The transcription factor combination MEF2 and KLF7 promotes axonal sprouting in the injured spinal cord with functional improvement and regeneration-associated gene expression	62
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	60
Using mass spectrometry to validate mouse models of tauopathy	60
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration	59
Evidence suggesting that microglia make amyloid from neuronally expressed APP: a hypothesis	58
RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD	56
Dementia with lewy bodies patients with high tau levels display unique proteome profiles	55
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease	54
The endotoxin hypothesis of Alzheimer’s disease	54
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis	53
Contribution of amyloid deposition from oligodendrocytes in a mouse model of Alzheimer’s disease	51
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	51
The role of n-3-derived specialised pro-resolving mediators (SPMs) in microglial mitochondrial respiration and inflammation resolution in Alzheimer’s disease	51
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns	51
Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease	51
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	50
Parkinson mice show functional and molecular changes in the gut long before motoric disease onset	49
Correction: Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	49
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts	48
SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer’s disease	47
Cerebrospinal fluid proteome profiling across the Alzheimer’s disease continuum: a step towards solving the equation for ‘X’	47
Mechanisms of astrocyte aging in reactivity and disease	47
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis	46
Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	45
VCP suppresses proteopathic seeding in neurons	45
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery	44
Sex specific molecular networks and key drivers of Alzheimer’s disease	43
Wild-type FUS corrects ALS-like disease induced by cytoplasmic mutant FUS through autoregulation	42
Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans	41
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP	39
Correction: Blood–brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	39
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice	38
SRSF1-dependent inhibition of C9ORF72-repeat RNA nuclear export: genome-wide mechanisms for neuroprotection in amyotrophic lateral sclerosis	38
Neuropathology and molecular diagnosis of Synucleinopathies	38

NF-κB is a critical mediator of post-mitotic senescence in oligodendrocytes and subsequent white matter loss	38
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	37
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer’s disease	37
Correction: Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	36
Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience	36
Increased expression of mesencephalic astrocyte-derived neurotrophic factor (MANF) contributes to synapse loss in Alzheimer’s disease	36
Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology	35
Nuclear pore and nucleocytoplasmic transport impairment in oxidative stress-induced neurodegeneration: relevance to molecular mechanisms in Pathogenesis of Parkinson’s and other related neurodegenerat	34
Therapeutic potential of APP antisense oligonucleotides for Alzheimer’s disease and down syndrome-related Alzheimer’s disease	34
Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy	34
MicroRNA-100-5p and microRNA-298-5p released from apoptotic cortical neurons are endogenous Toll-like receptor 7/8 ligands that contribute to neurodegeneration	34
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration	33
Pathological characteristics of axons and alterations of proteomic and lipidomic profiles in midbrain dopaminergic neurodegeneration induced by WDR45-deficiency	33
CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice	33
The role of inflammasomes in vascular cognitive impairment	33
Blood platelet factor 4: the elixir of brain rejuvenation	32
Correction: Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model	32
Age-dependent progression from clearance to vulnerability in the early response of periventricular microglia to α-synuclein toxic species	31
Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease	31
TDP-43 seeding activity in the olfactory mucosa of patients with amyotrophic lateral sclerosis	31
Targeted long-read sequencing to quantify methylation of the C9orf72 repeat expansion	31
Seeding activity of skin misfolded tau as a biomarker for tauopathies	31
Elevated nuclear TDP-43 induces constitutive exon skipping	30
Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer’s disease	30
Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature	30
Microglial ferroptotic stress causes non-cell autonomous neuronal death	30
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential	30
Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	30
BACE1 regulates expression of Clusterin in astrocytes for enhancing clearance of β-amyloid peptides	30